CFG
CRL icon

Clayton Financial Group’s Charles River Laboratories CRL Stock Holding History

Clayton Financial Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4
Closed -$690 – 178
2026
Q1 		$690 Sell
4
-5
-56% -$927 ﹤0.01% 583
2025
Q4 		$1.8K Buy
+9
New +$1.63K ﹤0.01% 475

Other funds holding CRL

CB
Cooke & Bieler Philadelphia, Pennsylvania $8.65B AUM 9.66% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
CIM
Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
LKIM
Lawson Kroeker Investment Management Omaha, Nebraska $361M AUM 22.26% 1-Year Est. Return

Clayton Financial Group's CRL Position: Q2 2026 in Review

Clayton Financial Group sold out of Charles River Laboratories (CRL) in Q2 2026, closing a stake of 4 shares — an estimated $690 sold.

Clayton Financial Group first reported a position in CRL in Q4 2025 and held it in 2 quarters. The position peaked at $1.8K in Q4 2025. 161 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Clayton Financial Group reported no remaining Charles River Laboratories position as of Q2 2026 after selling out during the quarter.
  • Clayton Financial Group sold 4 Charles River Laboratories shares in Q2 2026, an estimated $690.
  • Clayton Financial Group first reported a position in Charles River Laboratories in Q4 2025 and held it in 2 quarters.
  • Clayton Financial Group's Charles River Laboratories position peaked at $1.8K in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Clayton Financial Group's 13F filing for Q2 2026, filed 20 Jul 2026.